DexCom, Inc. (DXCM) Announced Q1 2026 Earnings on April 30, 2026, Reporting "worldwide revenue of $1.19 billion" for the first quarter

For the first quarter of 2026, DexCom reported worldwide revenue of $1.19 billion, representing growth of 15% on a reported basis and 12% on an organic basis. U.S. revenue totaled $832 million for the first quarter, representing an increase of 11%.

International revenue grew 26%, totaling $360 million in the first quarter.

First quarter gross profit was $757.4 million or 63.5% of revenue.

Operating income was $264.4 million or 22.2% of revenue in the first quarter of 2026.

Net income for the first quarter was $216.3 million or $0.56 per share.

The company closed the quarter with approximately $2.4 billion of cash and cash equivalents.

Management highlighted strong demand for DexCom CGM globally, benefiting from broader access, new product launches, and continued active base growth. A key business update included the expansion of the DexCom G7 15-day system across all U.S. channels, featuring a new sensor algorithm and extended wear time.

The company noted strong first quarter share gains in the U.S. type 2 diabetes category, primarily from people with type 2 diabetes who are not on insulin.

Management announced a new reimbursement win, noting that Prime Therapeutics will begin covering DexCom CGM for all people with diabetes this summer, which puts the company on track to have commercial coverage for more than 7 million type 2 non-insulin lives by the end of the year.

The company shared notable product updates, including a complete redesign of the Stelo app to offer more AI-driven personalized insights and additional food logging capabilities.

DexCom is also expanding access within its pilot for the DexCom smart Basal feature.

For full year forward guidance, DexCom reaffirmed its prior revenue guidance of $5.16 billion to $5.25 billion.

The company reiterated its previous full year non-GAAP gross profit margin guidance of 63% to 64%, while increasing its non-GAAP operating profit margin guidance to 23% to 23.5% and its adjusted EBITDA margin guidance to 31% to 31.5% for the year.